Want to see MTNB full AI Analyst Report?
Matinas BioPharma (MTNB) AI Stock Analysis
Matinas BioPharma
(NYSE MKT:MTNB)
Matinas BioPharma receives the lowest possible score due to extreme fundamental and technical distress. The primary risks include a severely depleted balance sheet, significant solvency concerns, and an active NYSE delisting notice. Paired with a persistent technical downtrend, lack of revenue, and heavy reliance on external capital, the stock presents a highly precarious profile.
Matinas BioPharma (MTNB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $644.89K
- Dividend Yield
- ―
- Average Volume (3M)
- 91.64K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.99
- Revenue Growth
- ―
- EPS Growth
- 68.91%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Matinas BioPharma Business Overview & Revenue Model
Company Description
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology und...
Matinas BioPharma Earnings Call Summary
The earnings call presented a mixed picture, with notable progress in MAT2203 licensing and financial management, counterbalanced by the lack of revenue, delays in trial timelines, and challenges in oncology trials. The sentiment is cautiously optimistic but acknowledges the hurdles that need addressing.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Matinas BioPharma Q2 2024 earnings call, several key metrics and guidance updates were provided. The company reported a net loss of $5.7 million or $0.02 per share for the quarter, a slight improvement from the $6.1 million or $0.03 per share loss in the same period of 2023. Total costs and expenses decreased to $5.8 million from $6.2 million year-over-year, primarily due to reduced clinical development and administrative costs. Matinas did not report any revenue for the quarter, consistent with the previous year. Cash, cash equivalents, and marketable securities stood at $14.3 million as of June 30, 2024, an increase from $13.8 million at the end of 2023, bolstered by $10 million in gross proceeds from a registered direct offering. The company is advancing plans for the ORALTO Phase III trial for MAT2203, with ongoing preparations and a potential start in the fourth quarter of 2024. Additionally, Matinas has signed a nonbinding term sheet for the global rights to develop, manufacture, and commercialize MAT2203, with the final agreement potentially including upfront payments, development and commercial milestones, and royalties.
Matinas BioPharma Financial Statement Overview
Summary
The company generates zero revenue and possesses a critically depleted asset base of just $3.4 million. Despite management successfully narrowing net losses, ongoing cash burn and minimal equity highlight severe solvency risks.
Income Statement
25NegativeBalance Sheet
15Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 1.10M | 3.19M | 33.00K |
| Gross Profit | -107.00K | -456.00K | -972.00K | 155.00K | -13.49M | -14.55M |
| EBITDA | -6.27M | -9.89M | -19.19M | -22.00M | -20.10M | -22.50M |
| Net Income | -7.31M | -10.35M | -24.25M | -22.94M | -21.00M | -23.28M |
Balance Sheet | ||||||
| Total Assets | 3.41M | 7.21M | 12.64M | 25.10M | 78.87M | 61.33M |
| Cash, Cash Equivalents and Short-Term Investments | 761.00K | 4.00M | 7.28M | 13.76M | 28.81M | 49.62M |
| Total Debt | 6,000 | 1.35M | 2.89M | 3.56M | 4.12M | 4.70M |
| Total Liabilities | 1.61M | 2.38M | 5.05M | 5.86M | 42.23M | 8.83M |
| Stockholders Equity | 1.80M | 4.83M | 7.59M | 19.25M | 36.64M | 52.49M |
Cash Flow | ||||||
| Free Cash Flow | -6.42M | -7.01M | -15.88M | -15.50M | -20.05M | -15.48M |
| Operating Cash Flow | -6.42M | -7.01M | -15.88M | -15.28M | -19.16M | -15.22M |
| Investing Cash Flow | 335.00K | 335.00K | 9.21M | 13.24M | 4.88M | 16.77M |
| Financing Cash Flow | 121.00K | 3.39M | 9.17M | -7,000 | 79.00K | 6.96M |
Matinas BioPharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 1.51 is below the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.52, and below the 200-day MA of 7.00, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 33.10 is Neutral, neither overbought nor oversold. The STOCH value of 33.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.
Matinas BioPharma Risk Analysis
Matinas BioPharma disclosed 59 risk factors in its most recent earnings report. Matinas BioPharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMatinas BioPharma Peers Comparison
Overall Rating
APRE44Neutral
HCWB42Neutral
NCNA42Neutral
ADIL40Underperform- MTNB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| APRE | 44Neutral | $6.10M | -0.45 | -46.72% | ― | -99.38% | 53.42% |
| HCWB | 42Neutral | $2.46M | -0.02 | -142.16% | ― | 707.02% | 70.52% |
| NCNA | 42Neutral | $4.35M | -0.25 | -41.95% | ― | ― | 99.50% |
| ADIL | 40Underperform | $10.00M | -0.30 | -1693.21% | ― | ― | 45.78% |
| MTNB | 37Underperform | $1.48M | -0.08 | -181.45% | ― | ― | 68.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MTNB | Matinas BioPharma Holdings | 1.51 | -18.59 | -92.49% | |
| NCNA | Nucana Plc | 1.01 | -2.93 | -74.37% | |
| ADIL | Adial Pharma | 3.81 | -4.81 | -55.83% | |
| SILO | Silo Pharma Inc | 1.23 | -6.57 | -84.23% | |
| APRE | Aprea Therapeutics, Inc. | 0.48 | -0.92 | -65.43% | |
| HCWB | Hcw Biologics, Inc. | 1.10 | -20.50 | -94.91% |
Matinas BioPharma Corporate Events
Matinas BioPharma Implements One-for-Fifteen Reverse Stock Split
NeutralOn September 25, 2026, Matinas BioPharma filed a Certificate of Amendment in Delaware to implement a one-for-fifteen reverse stock split of its common stock, which became effective at 12:01 a.m. Eastern Time on September 28, 2026. Subject to NYSE Ame...
Matinas BioPharma Announces One-for-Fifteen Reverse Stock Split
NeutralOn September 16, 2026, Matinas BioPharma announced that its Board had approved a one-for-fifteen reverse stock split of its common stock, following stockholder authorization granted at the June 23, 2025 annual meeting. The reverse split will take eff...
Matinas BioPharma Faces NYSE American Compliance Challenges
NegativeOn August 31, 2026, Matinas BioPharma received a notice from NYSE American that it is not in compliance with the exchange’s continued listing standards, citing stockholders’ equity of $1.8 million as of June 30, 2026 and losses in its fiv...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026